CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Vivani Medical Presents Development Plans for Once- or Twice-Yearly Semaglutide Implant

By Public Technologies
  • Vivani Medical expects top-line results from its SLIM-1 Phase 1 trial of semaglutide implant NPM-139 in November 2026.
  • All SLIM-1 patients were successfully dosed in August 2026; a Phase 2 dose-ranging study is projected to start in 2027.
  • NPM-139 targets once- or twice-yearly dosing for chronic weight management in obese or overweight patients.
  • Novo Nordisk's evaluation of NPM-139 remains ongoing.
  • Cash runway is expected to fund the current operating plan, including key milestones, into mid-2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk